{"id":"gemeprost","rwe":[{"pmid":"40147023","year":"2025","title":"Expectant management for women with intrauterine fetal death during the mid-trimester of pregnancy that was complicated by placenta previa.","finding":"","journal":"The journal of obstetrics and gynaecology research","studyType":"Clinical Study"},{"pmid":"39098827","year":"2024","title":"Outcomes and complications of second-trimester induction of labor using laminaria and gemeprost: A single-center experience in Japan.","finding":"","journal":"The journal of obstetrics and gynaecology research","studyType":"Clinical Study"},{"pmid":"38013013","year":"2024","title":"Abortion medical management between 14-16 weeks' amenorrhea after French legislation deadline extension.","finding":"","journal":"Journal of gynecology obstetrics and human reproduction","studyType":"Clinical Study"},{"pmid":"37927767","year":"2023","title":"Exploring the Safety and Efficacy of Medical Termination of Pregnancy: A Comprehensive Review.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"37770978","year":"2023","title":"Triple repeated fetal congenital heart disease linked to PLD1 mutation: a case report.","finding":"","journal":"Journal of medical case reports","studyType":"Clinical Study"}],"tags":[{"label":"gemeprost","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G02AD03","category":"atc"},{"label":"Active","category":"status"},{"label":"Abortifacient Agents","category":"pharmacology"},{"label":"Abortifacient Agents, Nonsteroidal","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cergem","offLabel":[],"synonyms":["gemeprost","carprost","cergem","cervagem","cervageme"],"timeline":[],"approvals":[],"brandName":"Cergem","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"gemeprost","explanation":"In simple terms, prostaglandins are like messengers that help different parts of the body communicate with each other. Gemeprost is a synthetic version of these messengers, which can help to relax muscles and improve blood flow. This can be beneficial in treating conditions where these processes are disrupted.","oneSentence":"Gemeprost works by mimicking the action of prostaglandins, a group of hormone-like substances that play a role in various bodily functions.","technicalDetail":"Gemeprost is a prostaglandin E1 analogue that acts as a vasodilator and smooth muscle relaxant, exerting its effects through binding to specific receptors and stimulating adenylate cyclase activity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1284","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GEMEPROST","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GEMEPROST","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:55:54.554383","biosimilars":[],"competitors":[{"drugName":"dinoprost","drugSlug":"dinoprost","fdaApproval":"1976-05-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dinoprostone","drugSlug":"dinoprostone","fdaApproval":"1977-08-23","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"carboprost","drugSlug":"carboprost","fdaApproval":"1979-01-09","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"misoprostol","drugSlug":"misoprostol","fdaApproval":"1988-12-27","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"gemeprost","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dinoprost","brandName":"dinoprost","genericName":"dinoprost","approvalYear":"1976","relationship":"same-class"},{"drugId":"dinoprostone","brandName":"dinoprostone","genericName":"dinoprostone","approvalYear":"1977","relationship":"same-class"},{"drugId":"carboprost","brandName":"carboprost","genericName":"carboprost","approvalYear":"1979","relationship":"same-class"},{"drugId":"misoprostol","brandName":"misoprostol","genericName":"misoprostol","approvalYear":"1988","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05342467","phase":"PHASE2","title":"Gemeprost Versus Dinoprostone in First Trimester Miscarriages","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2022-11-11","conditions":["Missed Abortion","Medical; Abortion, Fetus","Incomplete Abortion"],"enrollment":101,"completionDate":"2024-10-28"},{"nctId":"NCT01860521","phase":"NA","title":"Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2011-09","conditions":["Medical; Abortion, Fetus"],"enrollment":104,"completionDate":"2013-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003970","UNII":"45KZB1FOLS","CHEBI":"CHEBI:135626","INN_ID":"4738","RXNORM":"12449","UMLSCUI":"C0044923","ChEMBL_ID":"CHEMBL1908315","KEGG_DRUG":"D02073","DRUGBANK_ID":"DB08964","PUBCHEM_CID":"5282237","SNOMEDCT_US":"326128005","MESH_SUPPLEMENTAL_RECORD_UI":"C021182"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":286,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"G02AD03","allCodes":["G02AD03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Apr","pmid":"40147023","title":"Expectant management for women with intrauterine fetal death during the mid-trimester of pregnancy that was complicated by placenta previa.","journal":"The journal of obstetrics and gynaecology research"},{"date":"2024 Sep","pmid":"39098827","title":"Outcomes and complications of second-trimester induction of labor using laminaria and gemeprost: A single-center experience in Japan.","journal":"The journal of obstetrics and gynaecology research"},{"date":"2024 Jan","pmid":"38013013","title":"Abortion medical management between 14-16 weeks' amenorrhea after French legislation deadline extension.","journal":"Journal of gynecology obstetrics and human reproduction"},{"date":"2023 Oct","pmid":"37927767","title":"Exploring the Safety and Efficacy of Medical Termination of Pregnancy: A Comprehensive Review.","journal":"Cureus"},{"date":"2023 Sep 29","pmid":"37770978","title":"Triple repeated fetal congenital heart disease linked to PLD1 mutation: a case report.","journal":"Journal of medical case reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cergem, also known as Gemeprost, is a small molecule drug in the gemeprost class. It is used to treat certain conditions, but its exact target and approved indications are unknown. The commercial status of Cergem is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its key safety considerations and pharmacological properties. As a result, Cergem is not widely recognized in the pharmaceutical industry.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}